Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL)

Historical Holders from Q2 2020 to Q3 2025

Symbol
ZNTL on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
64,729,188
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
52,767,851
Holdings value
$79,681,183
% of all portfolios
0.001%
Number of holders
97
Number of buys
40
Number of sells
-54
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Walters William T 9.9% +8.9% $10,081,500 +$786,500 7,050,000 +8.5% Walters William T 29 Jan 2025
Matrix Capital Management Company, LP 9.98% $9,689,960 6,459,973 Matrix Capital Management Company, LP 15 Dec 2025
BARCLAYS PLC 5.32% $5,800,588 3,841,449 Barclays PLC 30 Sep 2025
VANGUARD GROUP INC 4.59% $4,677,873 3,271,240 The Vanguard Group 31 Dec 2024
BlackRock, Inc. 2.2% $1,952,121 1,613,323 BlackRock, Inc. 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 1.3% -80% $1,272,555 -$4,059,076 902,521 -76.1% Millennium Management LLC 30 Sep 2025
FMR LLC 0.2% $251,484 175,863 FMR LLC 29 Nov 2024

Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 52,767,851 $79,681,183 -$3,987,959 $1.51 97
2025 Q2 55,655,238 $64,573,024 -$4,209,380 $1.16 115
2025 Q1 58,450,755 $92,928,558 -$20,527,901 $1.59 131
2024 Q4 64,418,043 $195,184,400 -$24,736,255 $3.03 141
2024 Q3 70,964,067 $261,154,970 -$21,635,153 $3.68 133
2024 Q2 76,565,937 $313,165,477 -$54,359,485 $4.09 142
2024 Q1 85,290,558 $1,344,227,610 +$67,005,140 $15.76 140
2023 Q4 81,068,438 $1,228,198,230 -$21,970,408 $15.15 118
2023 Q3 80,197,042 $1,608,751,464 -$51,643,382 $20.06 136
2023 Q2 82,228,758 $2,319,672,532 +$442,954,370 $28.21 131
2023 Q1 67,021,594 $1,152,767,927 +$44,945,526 $17.2 108
2022 Q4 64,360,813 $1,296,145,033 +$105,231,060 $20.14 106
2022 Q3 58,811,479 $1,273,846,102 -$54,003,564 $21.66 116
2022 Q2 58,254,677 $1,636,896,016 +$359,446,058 $28.1 115
2022 Q1 44,437,538 $2,050,628,439 +$49,057,461 $46.14 123
2021 Q4 42,987,158 $3,611,907,936 +$90,022,119 $84.06 134
2021 Q3 41,250,292 $2,749,252,645 +$115,288,600 $66.64 114
2021 Q2 39,699,603 $2,112,018,735 +$205,833,024 $53.2 117
2021 Q1 36,327,192 $1,576,156,109 -$55,960,381 $43.39 93
2020 Q4 37,299,066 $1,937,340,198 +$309,645,949 $51.94 104
2020 Q3 31,635,340 $1,033,195,545 +$169,604,096 $32.69 65
2020 Q2 26,858,048 $1,282,608,905 +$1,282,608,902 $48.02 61